BR112022015827A2 - Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco - Google Patents

Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco

Info

Publication number
BR112022015827A2
BR112022015827A2 BR112022015827A BR112022015827A BR112022015827A2 BR 112022015827 A2 BR112022015827 A2 BR 112022015827A2 BR 112022015827 A BR112022015827 A BR 112022015827A BR 112022015827 A BR112022015827 A BR 112022015827A BR 112022015827 A2 BR112022015827 A2 BR 112022015827A2
Authority
BR
Brazil
Prior art keywords
bladder cancer
treatment
tyrosine kinase
kinase inhibitors
high risk
Prior art date
Application number
BR112022015827A
Other languages
English (en)
Portuguese (pt)
Inventor
Monga Manish
Ali Baig Mahadi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022015827A2 publication Critical patent/BR112022015827A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022015827A 2020-02-12 2021-02-11 Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco BR112022015827A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US202063118475P 2020-11-25 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
BR112022015827A2 true BR112022015827A2 (pt) 2022-10-04

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015827A BR112022015827A2 (pt) 2020-02-12 2021-02-11 Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco

Country Status (14)

Country Link
US (1) US20230110113A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103185A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023513704A (cg-RX-API-DMAC7.html)
KR (1) KR20220140781A (cg-RX-API-DMAC7.html)
CN (1) CN115103678A (cg-RX-API-DMAC7.html)
AU (1) AU2021220285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015827A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162962A1 (cg-RX-API-DMAC7.html)
IL (1) IL295514A (cg-RX-API-DMAC7.html)
JO (1) JOP20220182A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009905A (cg-RX-API-DMAC7.html)
PH (1) PH12022552093A1 (cg-RX-API-DMAC7.html)
TW (1) TW202143970A (cg-RX-API-DMAC7.html)
WO (1) WO2021160764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
JP2025506402A (ja) * 2022-02-04 2025-03-11 ヤンセン ファーマシューティカ エヌ.ベー. 転移性去勢抵抗性前立腺癌及びhrr変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン+プレドニゾン
WO2023159216A1 (en) * 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
IL322667A (en) * 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
KR20250148646A (ko) * 2023-02-13 2025-10-14 얀센 파마슈티카 엔브이 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
CN121891539A (zh) * 2026-02-06 2026-04-21 深圳大学 一种靶向iCAFs亚群的FGF2抑制剂组合物及其在膀胱癌防治中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
JP2023513704A (ja) 2023-04-03
PH12022552093A1 (en) 2023-11-29
JOP20220182A1 (ar) 2023-01-30
KR20220140781A (ko) 2022-10-18
MX2022009905A (es) 2022-08-25
JP2026097934A (ja) 2026-06-16
CN115103678A (zh) 2022-09-23
EP4103185A1 (en) 2022-12-21
CA3162962A1 (en) 2021-08-19
WO2021160764A1 (en) 2021-08-19
TW202143970A (zh) 2021-12-01
IL295514A (en) 2022-10-01
US20230110113A1 (en) 2023-04-13
AU2021220285A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
MX2022009905A (es) Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.
BR112022024729A2 (pt) Inibidores de quinases do receptor do fator de crescimento de fibroblastos
CO2021017981A2 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
BR112017007769A2 (pt) compostos e composições para modulação de atividades de cinase de egfr mutante
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
BR112021019203A2 (pt) Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial
MX2023011853A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer.
CO2024009144A2 (es) Inhibidores de cinasa met
BR112022023519A2 (pt) Tkis de egfr para uso no tratamento de câncer de pulmão de células não pequenas
MX2025001982A (es) Inhibidores de kif18a y usos de estos
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2024011959A (es) Inhibidores de la tirosina cinasa del receptor del factor de crecimiento epidérmico (egfr) junto con un inhibidor de la akt para el tratamiento del cáncer.
MX2025008454A (es) Inhibidores de mptp
PY1886949A (es) Inhibidor del receptor del factor de crecimiento epidérmico
BR112021019446A2 (pt) Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2025009445A (es) Inhibidores de la tirosina quinasa fgfr para el tratamiento del cáncer de vejiga sin invasión muscular de riesgo alto
BR112021019819A2 (pt) Combinações de inibidores de transcrição e inibidores dos pontos de controle imunológicos para o tratamento da doença
MX2024011197A (es) Combinaciones que comprenden inhibidores de metap2 para el tratamiento de cancer.
BRPI0816823A8 (pt) Formulação contendo composto inibidor de quinase dependente de ciclina e método de tratamento de tumores que a utiliza
CA3281325A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
CL2025002032A1 (es) Inhibidores del egfr selectivos de mutantes
HK40085988A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
MX2025000325A (es) Inhibidores de tirosina cinasa del receptor del factor de crecimiento epidermico en combinacion con inhibidores del receptor del factor de crecimiento de hepatocitos (hgf) para el tratamiento del cancer